Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1

HM Chang, R Moudgil, T Scarabelli… - Journal of the American …, 2017 - jacc.org
Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines

H Abdullah-Koolmees, AM Van Keulen… - Frontiers in …, 2021 - frontiersin.org
Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the …

MJ Ehrhardt, JM Leerink, RL Mulder… - The Lancet …, 2023 - thelancet.com
Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Hair cortisol analysis: An update on methodological considerations and clinical applications

MJE Greff, JM Levine, AM Abuzgaia, AA Elzagallaai… - Clinical …, 2019 - Elsevier
Background Hair cortisol analysis is increasingly being appreciated and applied in both
research and medicine, aiding endocrinologists with diagnosis. Content We provide an …

[HTML][HTML] Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy

Y Chen, S Shi, Y Dai - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …

Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity

T Magdy, M Jouni, HH Kuo, CJ Weddle, D Lyra-Leite… - Circulation, 2022 - Am Heart Assoc
Background: Multiple pharmacogenomic studies have identified the synonymous genomic
variant rs7853758 (G> A, L461L) and the intronic variant rs885004 in SLC28A3 (solute …

[HTML][HTML] RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy

T Magdy, Z Jiang, M Jouni, H Fonoudi, D Lyra-Leite… - Cell stem cell, 2021 - cell.com
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of
malignancies, but its use is limited by dose-dependent cardiotoxicity. A recent genome-wide …

Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review

JM Leerink, EC de Baat, EAM Feijen, L Bellersen… - Cardio Oncology, 2020 - jacc.org
Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

[HTML][HTML] Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой …

ЮА Васюк, ГЕ Гендлин, ЕИ Емелина… - Российский …, 2021 - cyberleninka.ru
АВ—атриовентрикулярный (ая) АГ—артериальная гипертензия АД—артериальное
давление АТ—артериальный тромбоз АТО—атеротромботические осложнения АТФ …

Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment

EJ Chow, KJ Leger, NS Bhatt… - Cardiovascular …, 2019 - academic.oup.com
With 5-year survival of children with cancer exceeding 80% in developed countries,
premature cardiovascular disease is now a major cause of early morbidity and mortality. In …